INTRODUCTION
Adoptive T-cell immunotherapy has risen to the forefront of treatment approaches for cancer. In particular, T cells engineered to express chimeric antigen receptors (CARs) have demonstrated impressive clinical efficacy with significant improvements in patient outcomes for a number of B-cell malignancies [1,2,3
. Expanding the use of CAR T-cell therapy to solid cancers is proving less tractable and is an area of intense research. Enhancements in current CAR T-cell design are under active investigation, with preclinical studies and retrospective analyses of clinical trials aimed at broadening their utility for multiple cancer types. Optimization of this therapeutic approach can be broken down into several components: the CAR design, the T-cell population and ex-vivo expansion methods, the tumor microenvironment, and safety considerations (Fig. 1) . Addressing each of these components will be critical to unleash the full potential of CAR T cells. The current review covers the status of CAR T-cell therapy, discussing both preclinical and clinical studies that shape our up-to-date knowledge and future prospects for this exciting immunotherapy approach.
MECHANICS OF CHIMERIC ANTIGEN RECEPTOR T-CELL ENGINEERING
primarily because of suboptimal persistence of the adoptively transferred cells [6] [7] [8] . Next-generation CARs have focused on refining T cells for improved persistence, expansion, and optimal antitumor activity. Below, we will summarize recent advancements in optimizing the therapeutic product through modified CAR designs and T-cell expansion protocols.
Advances in chimeric antigen receptor design
CARs are modular synthetic immunoreceptors consisting of three major functional components -the antigen-binding domain, the extracellular linker/spacer, and the intracellular signaling domain (Fig. 1 ). Together these building blocks aim to recapitulate native T-cell function, including antigen-dependent cytokine production, proliferation, and serial tumor cell killing. Although many of the refinements in CAR design have been determined empirically, general principles are emerging as greater panels of CARs are generated and compared side-by-side in preclinical studies and in patients.
The antigen-binding domain is most commonly composed of a single-chain variable fragment (scFv) derived from a monoclonal antibody, or in certain instances a receptor ligand. CARs directly recognize cell surface antigens in an MHC-independent fashion, rendering them universal for all patients and insensitive to tumor escape by MHC downregulation. Although the antigen-binding domain determines the overall specificity of the CAR and is important for predicting the potential for offtumor toxicities, questions remain regarding optimal CAR binding affinity. Several groups report that, similar to the T-cell receptor (TCR) [9] , CAR antigen binding requires a minimum affinity for Tcell activation, beyond which T-cell function is not significantly enhanced [10,11 & ,12] . Modulating CAR affinity, however, may be a strategy to finetune the level of antigen expression required for T-cell activation [10, 12, 13] , enhancing tumor selectivity for overexpressed self-antigens. In addition to antigen-binding affinity, epitope location may also be an important parameter for an optimized antigen-binding domain. For instance, studies evaluating CD22-specific CARs find that scFv binding to membrane-proximal epitopes improves CAR T-cell effector function and invivo antitumor activity as compared with scFvs that recognize membranedistal epitopes [14, 15] . Although the majority of CARs developed to date target extracellular antigens, with recent successes in generating high-affinity antibodies to specific peptide-MHC complexes, targeting intracellular antigens with CAR T cells is now feasible, thus broadening the pool of potential tumor-associated antigen targets [16] .
The intracellular signaling domain has been extensively evaluated both preclinically and clinically and can greatly impact the functional activity of CARs. A major advancement in 'first-generation' CAR design was achieved by addition of a costimulatory signal engineered in series with the CD3z activation domain (reviewed in [17] ). These 'second-generation' CARs typically incorporate the intracellular costimulatory domain of CD28 or 4-1BB, enhancing CAR T-cell function via increased cytokine production, T-cell proliferation, and killing in the setting of recursive exposure to antigen [18] [19] [20] [21] 
KEY POINTS
Major challenges exist to successfully extend CAR T-cell therapy beyond CD19-CARs for B-cell malignancies and effectively translate to other hematological malignancies and solid cancers.
CAR design and T-cell manufacturing are intrinsic variables that define the CAR T-cell product, and are critical determinants of overall therapy, likely to be empirically determined for each tumor antigen and cancer type.
Extrinsic factors related to the tumor microenvironment that impact the ability of CAR T cells to penetrate the tumor, retain potency within the hostile tumor microenvironment and overcome antigen heterogeneity of the tumor, have spurred more complex CAR T-cell engineering strategies and combination therapies. [31] [32] [33] , and these CAR designs are currently being clinically evaluated. Although few studies have addressed the contribution of the transmembrane domain, it likely plays an important role in expression stability and function of the CAR [34] . Further studies are warranted to elucidate the full impact of these structural components in CAR design.
Antigen-binding, extracellular spacer, and intracellular signaling domains cooperatively modulate the effectiveness and durability of CAR T-cell-mediated antitumor immunity. Examples of this interplay include recent reports that constitutive CAR signaling, mediated through scFv fragment aggregation in the absence of antigen, results in T-cell exhaustion and inferior in-vivo antitumor efficacy [35 & ,36]. These exhaustion-related adverse effects are enhanced by CD28 costimulatory signaling, but reduced with 4-1BB [35 & ]. In addition, scFvs targeting membrane-proximal epitopes may benefit from longer spacer regions, which would not be necessary for membrane-distal epitopes [29] , again suggesting interdependence of CAR domains. It has also been suggested that the ability of the CAR to engage associated molecules within the endogenous TCR complex is required for optimal CAR function [37] . Thus, a detailed understanding of the integration of these structural components is crucial for optimal CAR design, and is an area of intense investigation.
T-cell subsets and ex-vivo expansion methods
An equally critical design component impacting therapeutic efficacy is the final T-cell phenotype of the manufactured product, which is influenced by both the starting population for genetic engineering and the ex-vivo expansion methods (reviewed in [38] ). Preclinical studies evaluating the optimal T-cell subtype for adoptive therapy -differentiated terminal effectors versus less-differentiated naive/memory subsets -have converged on the paradoxical finding that the most effective T-cell product in vivo inversely correlates with T-cell effector phenotype and in-vitro cytotoxicity potential. Instead, less-differentiated naïve (T N ), stem memory (T SCM ), and central memory (T CM ) T cells, defined by expression of lymphoid homing receptors CCR7 and CD62L, mediate superior in-vivo persistence and antitumor activity compared with more differentiated effector memory (T EM ) and short-lived effector (T EFF ) T cells (reviewed in [39] ). This has been established in syngeneic mouse models, with human T cells in xenograft mouse models, and in nonhuman primate studies [40] [41] [42] [43] [44] . Indeed, retrospective analyses from adoptive T-cell clinical trials find that the frequency of less-differentiated memory T cells, either T CM [1, 45] or T SCM [45,46 & ], positively correlates with T-cell persistence and clinical outcome.
Strategies for manufacturing less-differentiated T cells to enhance the efficacy of CAR therapy continue to evolve. As ex-vivo T-cell expansion inevitably drives T-cell differentiation, limiting culture time yields younger and more potent T-cell products [47] . In addition, manufacturing platform variations related to T-cell activation strategies, cytokine conditions, and CAR design [35 & ,36] critically define the immunophenotype and overall functional potency of the final CAR T-cell product. An integral step in ex-vivo T-cell expansion is TCR activation, with several platforms currently employed for production of clinical-grade T-cell products, including soluble anti-CD3 antibody (OKT3) in the presence of interleukin (IL)-2 cytokine [2], OKT3 and CD28 antibody costimulation [1,3
&& -5 && ], and coculture with antigen-presenting cells [48] (Fig. 1) . Although the use of OKT3 in the presence of IL-2 has demonstrated utility in expanding CD8 þ T cells over other activation methods [49] , a recent study suggests that OKT3/CD28 magnetic bead stimulation produces T cells with a younger phenotype that outperforms OKT3/IL-2 expanded cells in preclinical tumor models [50] . Both methodologies, however, have demonstrated clinical responses in the setting of CD19-CARs [1,2,3
. Inclusion of gc cytokines during ex-vivo manufacturing, including IL-2, IL-7, IL-15, and/or IL-21, promotes extended expansion of the engineered T cells (reviewed in [51] ). Historically, IL-2 has been utilized during the expansion process; however, it is well established that IL-2 promotes T-cell differentiation. Several recent studies demonstrate that cell products manufactured using alternative cytokine cocktails, including IL-7 and/or IL-15, maintain a more stem/central memory-like phenotype and display improved persistence and antitumor activity [44,46 & ]. Support with IL-21 also limits differentiation and improves memory CD8
þ T-cell yield [52, 53] , showing promising clinical responses [54] . In addition, the use of pharmacological immune modulators to perturb differentiation pathways is under investigation, including inhibition of glycolysis [55] , induction of Wnt/b-catenin signaling [56] , blockade of AKT [57] , and combinations thereof [58] .
Another approach to produce less-differentiated T-cell products is the selective enrichment of specific T-cell subsets with high self-renewal potential for CAR engineering. The majority of T-cell products manufactured for clinical application utilize unselected peripheral blood mononuclear cells, where the frequency of memory T-cell subsets, and the CD4:CD8 ratios can vary greatly from patient to patient. This variability could explain some differences in clinical responses between patients. Good manufacturing practices (GMP) platforms using magnetic bead isolation have been established to enrich defined central memory T-cell subsets [41, 59] , or to standardize CD4:CD8 ratios [60] , with the intent of overcoming this inherent variability. Other less frequent T-cell subsets, such as IL-17-producing T cells (Th17 and Tc17), are also being explored based on their stem-like memory characteristics and show promising therapeutic potential [23 61, 62] . Furthermore, the use of virus-specific memory T cells with known antigen specificity for CAR-engineering may provide protection against viral reactivation, and can be combined with a vaccination approach for specific expansion of CAR T cells either in vitro or in patients [63, 64] . As the field explores these rarer T-cell populations for CAR therapy, including T SCM [40, 44] , Th17 [61] , and virus-specific T cells [59] , or attempts to generate large banks of allogeneic T cells for an 'off-the-shelf' product [65, 66] , developing long-term expansion conditions that maintain a 'younger' T-cell phenotype becomes critical. Furthermore, as CAR T-cell therapy moves toward commercialization, these platforms need to become more streamlined, costeffective, reproducible, and amenable to clinical translation under GMP.
CHALLENGES FOR CLINICAL TRANSLATION OF CHIMERIC ANTIGEN RECEPTOR THERAPY
Thus far, the most responsive clinical setting for CAR T-cell therapy has been acute lymphoblastic leukemia (ALL), with complete response rates reported for greater than 70% of patients treated with CD19-CARs, independent of patient age, disease burden, or prior treatments, and importantly, across multiple ], GD2-CAR T cells for neuroblastoma [45] , and IL13Ra2-CAR T cells for glioblastoma [69 & ] hint at the therapeutic opportunities of CAR T cells for nonhematological solid cancers, these responses do not approach those of CD19-CAR T cells. Variations in overall response rates have highlighted critical aspects of the tumor microenvironment that exist in solid cancers, and even under the umbrella of B-cell malignancies. Therefore, beyond the aforementioned CAR T-cell intrinsic factors, addressing the extrinsic factors, including effective tumor penetration of T cells, the immunosuppressive tumor microenvironment, and tumor heterogeneity will be required to move beyond the current successes with CD19-CARs for ALL.
Effective tumor trafficking and penetration of T cells is critical for the success of adoptive T-cell therapy, and is influenced by T-cell delivery route and the tumor microenvironment. The most common route of administration is intravenous, with established efficacy against B-cell malignancies. An outstanding question remains as to whether nonsystemic routes of delivery may elicit more direct and durable therapy for solid tumors. For ]. Migration and invasion of adoptively transferred T cells is also regulated by various chemokines. For instance, tumor-derived C-C motif ligand-2 (CCL2) [74] and forced T-cell expression of its receptor, CCR2 [75] , promote tumor infiltration and increased functionality of CAR T cells. The continued development of strategies to augment CAR T-cell trafficking and infiltration of tumors will advance adoptive T-cell therapy application, particularly for solid cancers.
The immunosuppressive tumor microenvironment is also an area of intense focus, which can prevent effective infiltration of T cells, and suppress their survival and function once inside the tumor. CAR design modifications, including costimulatory signaling, may provide some protection against the immunosuppressive microenvironment, as CD28-containing CARs demonstrate resistance to CTLA-4-mediated inhibition in preclinical models of B-cell malignancies [76] . Several groups have generated CAR T cells engineered to secrete cytokines, such as IL-12 [77] [78] [79] , which can stimulate T-cell-mediated immune responses in the local tumor microenvironment. Likewise, Curran et al. [80] show that constitutive expression of CD40L in T cells supports endogenous immune responses and improves functionality of CD19-CAR T cells in lymphoma models. Combinatorial immunotherapy strategies are also emerging as promising approaches to overcome tumor-mediated immunosuppression and improve adoptive T-cell therapy, including the potential for PD-1 checkpoint inhibitors to augment CAR T-cell therapy [81] , or inhibition of molecular pathways that drive immunosuppression in solid cancers (reviewed in [82] ). For example, tumor expression of IDO, an enzyme that depletes tryptophan, severely impedes survival and expansion of CD19-CAR T cells [83 & ]. Likewise, the transcription factor STAT3 [84, 85] , along with one of its target genes, Arginase [86] , can greatly hamper adoptive T-cell therapy, suggesting that specific inhibitors of these suppressive pathways may be important strategies to boost CAR T-cell therapy. Lessons learned from other cellular immunotherapies have spurred new approaches toward releasing the immunosuppressive brakes to enhance adoptive CAR T-cell-mediated antitumor immunity.
Another major challenge for CAR immunotherapy is the heterogeneous expression of tumor antigens. In the CD19-CAR clinical trials to date, disease recurrence of CD19-negative or epitopemutant tumors has diminished remission duration [4 && ,5 && ,87]. For solid cancers, tumor heterogeneity and antigen escape are major drivers in tumor evasion of immunotherapy [88, 89] , and indeed outgrowth of antigen negative/low tumors has been demonstrated in early clinical studies with IL-13Ra2-specific CAR T cells for advanced glioma [69 & ]. Several strategies have been incorporated into CAR design to improve durability of therapy in the presence of tumor heterogeneity. Dual-targeting CARs enhance the activation of T cells against tumors that express multiple tumor antigens, which has been demonstrated with IL-13Ra2 and HER2 for gliomas [90] , HER2 and MUC1 for breast cancers [91] , and PSCA and PSMA for prostate cancers [92] . In addition, unleashing an endogenous immune response during adoptive T-cell therapy could promote antigen spreading to other tumor-specific neo-antigens, and thus reduce the potential for antigen escape [93, 94] . Multitargeting CARs hold promise for a more personalized medicine approach, as new targets are identified, new CARs are validated for safety and efficacy in the clinic, and novel patient screening procedures come online.
While enhancing potency and durability of CAR T-cell therapy has dominated recent investigations, safety considerations in the clinic are equally important. Of the serious toxicities associated with CD19-CAR T-cell therapy, the most common is cytokine release syndrome, which in its most severe form is commonly managed by using the anti-IL-6 receptor antibody tocilizumab with or without corticosteroids [95] . Off-tumor toxicity has not been a significant issue for CD19-CARs that also target normal B cells, as B-cell aplasia is clinically manageable, and often used as a surrogate marker for CD19-CAR T-cell functional duration [1,2,3 && -5 && ]. One of the biggest challenges for translating this approach to other cancers has been the identification of amenable antigens for immunological targeting [96] , as many cancer antigens have normal tissue expression that may cause on-target off-tumor toxicity [97] . The immunogenicity of nonphysiological CAR components is also an issue for safety and CAR persistence [72] . Humanizing scFvs is an important optimization step in CAR development to minimize potential anti-CAR immunogenicity [12, 13] . Other CAR-intrinsic strategies have been evaluated to address safety concerns with CAR T cells. One approach has been to transiently express CARs in T cells using nonviral methods to ensure limited persistence of the CAR-expressing T-cell product [98] [99] [100] . Although this approach requires repeat infusions of CAR T cells for clinical efficacy, the short lifespan of the engineered product may mitigate unmanageable toxicities.
A more direct approach to blunting undesirable side-effects is incorporation of suicide genes in CAR T cells to provide a safety net when targeting tumor Smart CARs engineered for cancer immunotherapy Priceman et al.
antigens that may also have low, but detectable, normal tissue expression. Examples include addition of iCaspase 9 for dimerization-induced apoptosis that has been shown to rapidly eliminate modified T cells in patients [101] , or engineering T cells to express specific cell surface antigens for immunologic targeting such as the truncated epidermal growth factor (EGF) receptor that has been shown to render modified T cells susceptible to anti-EGFR antibody (i.e. Erbitux) elimination in mice [102] . Other strategies are being evaluated in the preclinical setting, including dissociating CAR components for improved selectivity of tumors [91, 92, 103] , incorporating inhibitory CARs to reduce on-target off-tumor toxicity [104] , and potentially driving expression of CAR with regulated promoters to improve tumor selectivity. The incorporation of safety switches will be important additions to CAR designs as optimizations aim to improve the potency and durability of this therapy.
CONCLUSION
Although the excitement of CAR T cells has spread across the immunotherapy world, there are considerable unknowns in translating this therapy beyond CD19, to treat other hematological malignancies and solid cancers. Enthusiasm for adoptive T-cell therapy in the treatment of advanced cancers is producing tremendous efforts to address the challenges of CAR T-cell potency, persistence, patient safety, the immunosuppressive tumor microenvironment, and tumor heterogeneity. Effectively translating this technology beyond CD19-CARs will likely require sophisticated optimization and engineering innovations of CAR T-cell products to tackle each of these abovementioned hurdles. Preclinical studies and clinical investigations are currently underway to address many of these challenges in the field, and will likely continue to invigorate the development of CAR-based immunotherapies for a wide spectrum of malignancies.
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